Journal article
Phase I trial of a CD8( ) T-Cell peptide epitope-based vaccine for infectious mononucleosis
Suzanne L Elliott, Andreas Suhrbier, John J Miles, Greg Lawrence, Stephanie J Pye, Thuy T Le, Andrew Rosenstengel, Tam Nguyen, Anthony Allworth, Scott R Burrows, John Cox, David Pye, Denis J Moss, Mandvi Bharadwaj
JOURNAL OF VIROLOGY | AMER SOC MICROBIOLOGY | Published : 2008
DOI: 10.1128/JVI.01409-07
Abstract
A single blind, randomized, placebo-controlled, single-center phase I clinical trial of a CD8(+) T-cell peptide epitope vaccine against infectious mononucleosis was conducted with 14 HLA B*0801-positive, Epstein-Barr virus (EBV)-seronegative adults. The vaccine comprised the HLA B*0801-restricted peptide epitope FLRGRAYGL and tetanus toxoid formulated in a water-in-oil adjuvant, Montanide ISA 720. FLRGRAYGL-specific responses were detected in 8/9 peptide-vaccine recipients and 0/4 placebo vaccine recipients by gamma interferon enzyme-linked immunospot assay and/or limiting-dilution analysis. The same T-cell receptor Vbeta CDR3 sequence that is found in FLRGRAYGL-specific T cells from most EB..
View full abstractGrants
Awarded by NCI NIH HHS
Awarded by NATIONAL CANCER INSTITUTE